FOR VETERINARY USE ONLY

RAPİDOLL

PARAPOXVIRUS OVIS IMMUNOSTIMULANT

Dollvet

LYOPHILISATE FOR SUSPENSION FOR INJECTION AND SOLVENT

COMPOSITION:

Inactived Parapoxvirus ovis E(P)CK strain: Minimum 256 interferon units per ml.

Excipients

Lactalbumin Hydrolysate:	0,25 mg/dose
Sucrose:	0,50 mg/dose

IMMUNOLOGICAL PROPERTIES:

ATCvet code: QI02AX, QI03AX, QI04AX, QI05AX01, QI06AX, QI07AX
Pharmacotherapeutic group: Other immunologics (Non-specific immunostimulant)

INDICATIONS:

Used to increase non-specific immunity in horses, cattle, sheep, goats, cats and dogs and their newborn offspring. It increases the resistance of the organism against infections. It helps treatment by strengthening the effectiveness of the therapeutic intervention applied in diseases. By stimulating the immune system, it contributes to the development of the specific immune response to vaccination. Increases host resistance in stressful situations (transport or environmental conditions)

METHOD OF ADMINISTRATION AND DOSAGE:

Cats and dogs are administered 1 ml (1 dose) subcutaneously. Horses, cattle, sheep and goats are administered 2 ml (2 doses) intramuscularly.
In case of risk of infection, it is recommended to administer 3 doses with 48 hour intervals: to help prevent stress-induced illnesses, the first dose should be administered 3 to 1 day before the possible occurrence stress source, followed by 2 additional application with 48 hour intervals.

SPECIAL CLINICAL INFORMATION AND SPECIAL WARNINGS FOR TARGET SPECIES:

No special warning is required for target species.

ADVERSE EFFECTS:

Some animals may develop a temporary nodule at the application site. Rarely, anaphylactic reaction may develop in susceptible animals. In this case, symptomatic treatment (antihistamine/antiallergic drugs) should be applied.

INTERACTION WITH OTHER MEDICINAL PRODUCTS:

RAPİDOLL stimulates non-specific immunity, so when used in combination with other immunological products, it is expected to support the resulting response. Concurrent use with immunosuppressive products may result in suppression of the non-specific immune system.

SYMPTOMS, PRECAUTIONS AND ANTIDOTE IN CASE OF OVERDOSE:

No overdose studies have been conducted as it is an inactivated vaccine.

WITHDRAWAL PERIOD:

Withdrawal period is 0 day.

CONTRAINDICATIONS:

It has no known contraindications.

FOR VETERINARY USE ONLY

RAPİDOLL

PARAPOXVIRUS OVIS IMMUNOSTIMULANT

Dollvet

LYOPHILISATE FOR SUSPENSION FOR INJECTION AND SOLVENT

GENERAL WARNINGS:
"Keep out of reach of children"
"Consult your veterinarian before use and in case of an unexpected effect"

PRECAUTIONS AND RECOMMENDATIONS FOR VETERINARIANS:
The lyophilized pellet should be brought to room temperature before administration, reconstituted with solvent and shaken well until completely mixed. Opened bottles should be used within 6-8 hours. Aseptic needles and syringes should be used in each application.
In case of injuries that may occur during the application of the product, the area should be cleaned and disinfected.
The vaccine should only be administered by a veterinarian or a Veterinary health technician under the supervision of a veterinarian.

STORAGE CONDITIONS AND SHELF LIFE:
Lyophilisate for suspension for injection should be stored at +2/+8ºC and in the dark. Do not freeze.
Shelf life is 24 months. Opened vials should be used within 6-8 hours.
The solvent is stored in the dark and at temperatures lower than 25°C. Do not freeze. Shelf life is 24 months.

DISPOSAL OF WASTE AND WARNINGS FOR NON-TARGET SPECIES:
Following use of the products, residual materials should be destroyed by boiling, burning or immersing in a suitable disinfectant.

PRESENTATION:
RAPİDOLL is available as lyophilized pellets as 1 dose, 2 doses, 5 doses, 10 doses, 20 doses in Type 1 colorless glass vials, sealed with bromobutyl rubber stopper and aluminum cap.
The diluent for dissolving the lyophilized pellet is packaged in Type I colorless glass vials of 1 ml, 2 ml and 5 ml and Type II colorless glass vials of 10 ml and 20 ml.
RAPİDOLL in plastic vials and boxes in a box:
10 x 1 dose of lyophilized product and 10 x 1 ml of solvent (1 dose for cats and dogs after reconstitution). 10 x 2 doses of lyophilized product and 10 x 2 ml of solvent (after reconstitution, 2 doses for cats and dogs, 1 dose for horses, cattle,sheep and goat.)
1x 5 doses of lyophilized product and 5 ml of solvent (administered as 5 doses for cats and dogs after reconstitution). 1x10 dose of lyophilized product and 10 ml of solvent (after reconstitution, 10 doses for cats and dogs, 5 doses for horses, cattle, sheep and goat.)
1x20 doses of lyophilized product and 20 ml of solvent (after reconstitution, 20 doses for cats and dogs, 10 doses for horses, cattle, sheep and goat.) Not all packaging forms may be marketed.

LEAFLET APPROVAL DATE: 22.08.2023

DATE OF MARKETING AUTHORIZATION ISSUED BY THE MINISTRY OF AGRICULTURE AND FORESTRY: 22.08.2023

NAME AND ADDRESS OF MARKETING AUTHORIZATION HOLDER:
DOLLVET Biyoteknoloji A.Ş.
Konaklar Mah. Akasyalı Sok. No:10 Beşiktaş /İSTANBUL
Telephone: +90 212 422 02 01 **Fax:** +90 212 422 00 72 **E-mail:** dollvet@dollvet.com.tr

NAME AND ADDRESS OF MANUFACTURER:
DOLLVET Biyoteknoloji A.Ş.
Organize Sanayi Bölgesi Koçören OSB Mahallesi 106. Cadde No:6 Eyyübiye/ŞANLIURFA
Telephone: +90 414 369 11 33 **Fax:** +90 414 369 16 62 **E-mail:** dollvet@dollvet.com.tr

201016-R.01